

# Stratacel® - Enhancing Wound Healing in Facial Rejuvenation Procedures




Gold, M., Biron, J. (2019). 'Randomized, single-blinded, crossover study of a novel wound dressing vs current clinical practice after Percutaneous collagen induction therapy', *Journal of Cosmetic Dermatology*, 18(2), pp. 524-529.



Scan to read  
the original study

## Summary


20 patients were assessed in a randomized split-face in-patient controlled trial to explore the effectiveness of Stratacel®, a novel film-forming wound dressing, in the context of facial rejuvenation procedures, specifically Fractional Radiofrequency Microneedling (FRFM). Stratacel® is compared to standard of care (Aquaphor®, a petroleum-based ointment) to assess its impact on wound healing and post-procedural responses. The study aims to evaluate Stratacel's® ability to reduce inflammation, improve product properties (feel on skin, drying time and stickiness), promote faster healing, and in turn reduce patient downtime, thereby enhancing patient outcomes.




**Figure 1:** Evolution of erythema with the use of the two study products across visits.

## Results

- Stratacel® significantly reduced erythema as early as 2 days post-procedure. This reduction indicated a **faster transition to the wound healing phase, reducing patient downtime**, which in turn improves patient outcomes and enhanced cosmetic results. This acceleration also holds potential for **mitigating postinflammatory hyperpigmentation (PIH) risk**, especially in patients with darker skin types. (Figure 1,2)
- Patients favoured Stratacel® over the standard therapy regarding product properties such as feel on the skin, drying time, and stickiness. This contributed to a more positive treatment experience. (Figure 2)
- Stratacel® did not lead to any adverse reactions, affirming its suitability for post-operative wound care in facial rejuvenation procedures.



**Figure 2:** Reduction of erythema from baseline assessment at each study visit. Hemoglobin levels are presented as mean values  $\pm$  standard error mean.



**Figure 3:** A side-by-side comparison of Stratacel® and Aquaphor® in terms of key product properties (feel on skin, drying time, stickiness, etc.) at day 7 post-procedure. Bars are presented as mean values  $\pm$  standard error mean.

## Stratacel®: Reasons for Effectiveness

The findings of the clinical trial suggest that Stratacel®, offering substantial inflammation reduction and improved product attributes, should be considered first-line therapy for minimizing downtime after procedures like FRFM or other fractional and ablative energy-based treatments.

Gold, et al. (2019) states,  
*"The novel wound dressing (Stratacel®), reduced signs of acute inflammation following PCIT when compared to standard of care (Aquaphor®), without reporting adverse events and resulting in a more favorable outcome from a patient perspective."*